Some scholars deemed that V3 with more invasive tumor biology presented a worse response to crizotinib,17, 18 while some findings indicated that patients with V1 had more favorable PFS of crizotinib compared with non‐V119 and other studies suggested V2 had best response to crizotinib among ALK variants.20 This evidence concerns the gene ALK and neoplasm.